Abstract
Erectile dysfunction (ED) is a common disorder among men, with significant public health implications. Current therapies have certain limitations including efficacy and safety issues, necessitating the development of novel therapeutic strategies for ED. Nanotechnology-based drug delivery systems are being explored to overcome these limitations with promising in vitro and in vivo efficacies. In particular, lipid-based nanoparticles have generated considerable interest owing to their potential to enhance drug bioavailability, and decrease side effects and drug susceptibility to metabolism. This review summarizes the recent findings using lipid-based nanoparticles in ED therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 578-586 |
| Number of pages | 9 |
| Journal | International Journal of Impotence Research |
| Volume | 32 |
| Issue number | 6 |
| Early online date | Jan 2020 |
| DOIs | |
| Publication status | Published - Nov 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Transdermal drug-delivery
- Sildenafil citrate
- In-vitro
- Intracavernous alprostadil
- Ultradeformable vesicles
- Double-blind
- Rapid-onset
- 5 inhibitor
- Rat model
- Ex-vivo
Fingerprint
Dive into the research topics of 'Lipid-based nanoparticles in the treatment of erectile dysfunction'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver